Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 11/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.39 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19046486 | 0.98 | MAP1LC3B (0.40) | SIRT2SIRT1SIRT3SIRT5MAP1LC3B | |
| SCHEMBL22203014 | 0.98 | MAP1LC3B (0.40) | SIRT2SIRT1SIRT3SIRT5MAP1LC3B | |
| SCHEMBL18910972 | 0.98 | MAP1LC3B (0.40) | SIRT2SIRT1SIRT3SIRT5MAP1LC3B | |
| SCHEMBL19708322 | 0.98 | MAP1LC3B (0.40) | SIRT2SIRT1SIRT3SIRT5MAP1LC3B | |
| SCHEMBL21477708 | 0.95 | SIRT2 (0.40) | SIRT2SIRT1SIRT3SIRT5MAP1LC3B | |
| SCHEMBL21943700 | 0.93 | FAP (0.42) | SIRT2SIRT1SIRT3SIRT5MAP1LC3B | |
| SCHEMBL19502733 | 0.93 | FAP (0.42) | SIRT2SIRT1SIRT3SIRT5MAP1LC3B | |
| SCHEMBL23436442 | 0.92 | SIRT2 (0.41) | SIRT2SIRT1SIRT3SIRT5MAP1LC3B | |
| SCHEMBL21013625 | 0.92 | SIRT5 (0.40) | SIRT2SIRT1SIRT3SIRT5MAP1LC3B | |
| SCHEMBL22138815 | 0.91 | FAP (0.39) | SIRT2SIRT1SIRT3SIRT5MAP1LC3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230128499-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES | NOVARTIS AG (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | CD44, SIGLEC7, SIGLEC9 | SIRT2 3528/4885SIRT1 4047/4885SIRT3 3502/4885 |
| US-20230128499-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES | CD2, CD22, CD2BP2 | SIRT2 4783/4885SIRT1 4798/4885SIRT3 4839/4885 |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | SIRT2 4689/4885SIRT1 4857/4885SIRT3 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.